Dr. Vladislav Bergo is the founder and Chief Scientific Officer of Adeptrix Corporation, a biotechnology company located in Beverly, Massachusetts. Adeptrix is building a new generation of biological microarrays that employ both mass spectrometry and fluorescence imaging as the analytical readout. Dr. Bergo is an inventor of several patents in the field of mass spectrometry-based bioassays. He is currently a Principal Investigator supported by Small Business Innovation Research (SBIR) grant awards from the National Institutes of Health and the National Science Foundation.
Dr. Bergo received his Ph.D. in Biophysics from Boston University in 2004 and later was a post-doctoral researcher at the University of Texas Health Science Center in Houston, TX where he studied the mechanisms of signal transduction in archaeabacteria and marine proteobacteria.